Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 9/20 | 0.39 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203696 | 1.00 | HDAC6 (0.43) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL13203698 | 0.84 | HDAC6 (0.60) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2970308 | 0.84 | HDAC6 (0.60) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL6227269 | 0.83 | HDAC3 (0.30) | HDAC6HDAC3 | |
| SCHEMBL13203690 | 0.80 | VDR (0.54) | HDAC6HDAC3VDRAR | |
| SCHEMBL2965714 | 0.80 | VDR (0.54) | HDAC6HDAC3VDRAR | |
| SCHEMBL13798729 | 0.79 | HDAC6 (0.45) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2971492 | 0.78 | VDR (0.45) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL13203692 | 0.78 | VDR (0.45) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2971593 | 0.77 | VDR (0.65) | HDAC6HDAC3VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090018058-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1587906-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1565422-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP24A1, CYP2R1 | HDAC6 4639/4885HDAC3 2546/4885HDAC1 3029/4885 |
| US-20090018058-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | HDAC6 4137/4885HDAC3 1685/4885HDAC1 2890/4885 |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | HDAC6 4452/4885HDAC3 2892/4885HDAC1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.